Breast cancer triple negative is the mammary tumor that more scientific advances will have in the coming years, as predicted by the director of the Breast Cancer Unit of IOB Institute of Oncology, Javier Cortés, during the annual meeting of the American Society of Oncology (ASCO, for its acronym in English), held in Chicago (United States).
And is that, although in this meeting have not presented data “very novel” regarding this tumor, the least common of all breast cancers but the most aggressive, Cortés has advanced that at the next Congress of the Society European Oncology (ESMO), which will be held in September in Barcelona, and the Breast Cancer Symposium, to be organized at the end of the year in San Antonio (United States), will present “very important” data “About it.
“The first data on immunotherapy in triple negative breast cancer will be shown,” he assured, to inform that hormone and HER2 positive breast cancer will also be presented. “The best of this year at ASCO is coming and we will know it at ESMO and at the San Antonio meeting,” he added.
However, the doctor has referred to different studies presented at the American Congress of Oncology as for example, the study 'Monaleesa-7' in advanced breast cancer or metastatic hormone receptor positive and receptor 2 human negative epidermal growth factor, which The first time “in many years” has shown an “important” improvement in the survival of these patients.
Likewise, he continues, there have been studies showing survival rates of up to 94 percent in women with early stage HER2 breast cancer; or optimizations of treatments in advanced HER2 breast cancer. Finally, in HER2 negative, there has been “another twist” to better understand which patients do not need chemotherapy, especially in the case of younger women.